Improving cancer immunotherapy by targeting IL-1

Interleukin-1 (IL-1) is an inflammatory cytokine associated with tumor invasiveness and metastasis. We recently found that baseline IL-1 in melanomas promoted resistance to immunotherapy by creating an immunosuppressive tumor microenvironment and that IL-1 produced in response to CD40 agonist also i...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Zhilan, Singh, Shubhra, Singh, Manisha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632280/
https://www.ncbi.nlm.nih.gov/pubmed/34858734
http://dx.doi.org/10.1080/2162402X.2021.2008111
_version_ 1784607727916417024
author Xiao, Zhilan
Singh, Shubhra
Singh, Manisha
author_facet Xiao, Zhilan
Singh, Shubhra
Singh, Manisha
author_sort Xiao, Zhilan
collection PubMed
description Interleukin-1 (IL-1) is an inflammatory cytokine associated with tumor invasiveness and metastasis. We recently found that baseline IL-1 in melanomas promoted resistance to immunotherapy by creating an immunosuppressive tumor microenvironment and that IL-1 produced in response to CD40 agonist also induced resistance to therapy. Here, we discuss how naturally occurring and immunotherapy-induced IL-1 in tumors causes immune suppression and resistance to immunotherapy, and we discuss targeting the IL-1 pathway to enhance the efficacy of immunotherapy.
format Online
Article
Text
id pubmed-8632280
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-86322802021-12-01 Improving cancer immunotherapy by targeting IL-1 Xiao, Zhilan Singh, Shubhra Singh, Manisha Oncoimmunology Research Article Interleukin-1 (IL-1) is an inflammatory cytokine associated with tumor invasiveness and metastasis. We recently found that baseline IL-1 in melanomas promoted resistance to immunotherapy by creating an immunosuppressive tumor microenvironment and that IL-1 produced in response to CD40 agonist also induced resistance to therapy. Here, we discuss how naturally occurring and immunotherapy-induced IL-1 in tumors causes immune suppression and resistance to immunotherapy, and we discuss targeting the IL-1 pathway to enhance the efficacy of immunotherapy. Taylor & Francis 2021-11-25 /pmc/articles/PMC8632280/ /pubmed/34858734 http://dx.doi.org/10.1080/2162402X.2021.2008111 Text en © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Xiao, Zhilan
Singh, Shubhra
Singh, Manisha
Improving cancer immunotherapy by targeting IL-1
title Improving cancer immunotherapy by targeting IL-1
title_full Improving cancer immunotherapy by targeting IL-1
title_fullStr Improving cancer immunotherapy by targeting IL-1
title_full_unstemmed Improving cancer immunotherapy by targeting IL-1
title_short Improving cancer immunotherapy by targeting IL-1
title_sort improving cancer immunotherapy by targeting il-1
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632280/
https://www.ncbi.nlm.nih.gov/pubmed/34858734
http://dx.doi.org/10.1080/2162402X.2021.2008111
work_keys_str_mv AT xiaozhilan improvingcancerimmunotherapybytargetingil1
AT singhshubhra improvingcancerimmunotherapybytargetingil1
AT singhmanisha improvingcancerimmunotherapybytargetingil1

Ejemplares similares